An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

Matthew Hellmann; Suresh Ramalingam; Martin Reck; Ken OByrne; Luis Paz-Ares; Christopher T Harbison; Prabhu Bhagavatheeswaran; Faith Nathan; Julie Brahmer

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

【24h】

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

机译：一项针对nivolumab初治IV期或复发性非小细胞肺癌（NSCLC）患者的nivolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的开放标签随机III期试验（CheckMate 227）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2015年第s2期|共页
作者
Matthew Hellmann; Suresh Ramalingam; Martin Reck; Ken OByrne; Luis Paz-Ares; Christopher T Harbison; Prabhu Bhagavatheeswaran; Faith Nathan; Julie Brahmer;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J] . Reck Martin, Schenker Michael, Lee Ki Hyeong, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗，具有高肿瘤突变负担：患者报告的结果由随机，开放标签，III期检查培育227试验结果
2. CheckMate-227 shows superior progression-free Survival for Nivolumab in combination with Ipilimumab versus Chemotherapy in the First-line Treatment of non-small cell Lung Cancer Patients with high Tumor Mutational Burden [J] . Oncology research and treatment. . 2018,第4期

机译：checkmate-227显示了Nivolumab的优异进展生存期与Ipilimalab与化疗组合，在肿瘤突变负担的非小细胞肺癌患者的一线治疗中
3. CheckMate-227 shows superior progression-free Survival for Nivolumab in Combination with Ipilimumab versus Chemotherapy in the First-line Treatment of Patients with non-small cell Lung Cancer during high Tumor Mutation Burden [J] . Oncology research and treatment. . 2018,第3期

机译：checkmate-227显示了Nivolumab与Ipilimumab与化疗组合在高肿瘤突变负担期间的患者的肝脏和化疗中的卓越的进展生存
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [O] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, 2015

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）
7. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [O] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, 2015

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

著录项

相似文献

相关主题

期刊订阅